自新冠疫情以來(lái)，廈門寶太生物科技股份有限公司高度關(guān)注SARS-CoV-2在全球范圍內(nèi)出現(xiàn)的突變，并與廈門大學(xué)張永有教授緊密合作，持續(xù)跟蹤分析SARS-CoV-2突變，以確保寶太新冠抗原試劑有效檢出出現(xiàn)的突變毒株。我們積極跟蹤WHO、GISAID、UK等報(bào)告的SARS-CoV-2突變株，利用相應(yīng)的重組N蛋白對(duì)寶太生產(chǎn)的新冠抗原檢測(cè)試劑進(jìn)行了評(píng)估和驗(yàn)證。結(jié)果顯示本公司生產(chǎn)的新冠抗原檢測(cè)試劑可以有效檢出阿爾法（Alpha, B.1.1.7），貝塔（Beta, B.1.351），德?tīng)査―elta, B.1.617.2），奧密克戎（Omicron, B.1.1.529）。
Since the outbreak of COVID-19, Xiamen Biotime Biotechnology Co., Ltd. has paid high attention to the mutations of SARS-CoV-2 around the world, and closely cooperated with Professor Zhang Yongyou of Xiamen University to keep tracking and analyzing the mutations of SARS-CoV-2, ensuring that the novel coronavirus antigen kits produced by Biotime can effectively detect the present mutant strains. We actively followed up the SARS-CoV-2 mutant strains reported by WHO, GISAID and UK, and evaluated and verified the novel coronavirus antigen test kits produced by Biotime with corresponding recombinant N proteins. The results showed that the novel coronavirus antigen test kits produced by our company could efficiently detect Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529).
Omicron (B.1.1.529)兩端測(cè)序結(jié)果
Sequence from both sides
Omicron (B.1.1.529)實(shí)驗(yàn)室測(cè)結(jié)果
Wet lab test result
